New Market - June 29, 2017
Immunovia establishes US headquarters
The company has chosen Boston, Massachusetts USA, as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB. This new site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilities for commercialization, covering marketing, sales and customer support. A team have been […]
In a new job - May 29, 2017
Sectra establish a new direct sales operation in Canada
Sectra has established a new direct sales operation entitled Sectra Canada Inc. The company hopes that an increased local presence will enable Sectra to focus and tailor its offerings to the specific workflow requirements of the Canadian market. The office will be located in Toronto and is expected to be operational by September 2017. “To […]
New Market - May 19, 2017
Sobi’s Elocta approved in Saudi Arabia
Swedish Orphan Biovitrum announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A. Elocta is the first extended half-life and recombinant factor VIII Fc fusion protein therapy approved […]
New Market - March 28, 2017
AstraZeneca’s Tagrisso approved in China
The China Food and Drug Administration has granted marketing authorisation for Tagrisso, 40 mg and 80mg once-daily oral tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy. “This is an important […]
CDMO - March 27, 2017
Recipharm manufactures to the Japanese market
Recipharm has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden will produce and deliver to Sato. […]
MedTech Business - January 24, 2017
OssDsign announces FDA clearance
OssDsign has received 510(k) clearance by the US FDA for marketing of OSSDSIGN Cranial PSI in the USA. “Receiving FDA clearance for our flagship product OSSDSIGN Cranial is extremely positive news. This means we can continue working according to our existing plan of launching OSSDSIGN Cranial on the US market in Q1 2017. We are […]
